Bernard BF - Search Results

1

Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model.

Breeman WA, Mearadji A, Capello A, Bernard BF, van Eijck CH, Krenning EP, de Jong M. Breeman WA, et al. Among authors: bernard bf. Int J Cancer. 2003 Apr 10;104(3):376-9. doi: 10.1002/ijc.10952. Int J Cancer. 2003. PMID: 12569562

2

111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.

Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M. Capello A, et al. Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1288-95. doi: 10.1007/s00259-005-1877-x. Epub 2005 Jul 15. Eur J Nucl Med Mol Imaging. 2005. PMID: 16021448

3

Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.

Rolleman EJ, Forrer F, Bernard B, Bijster M, Vermeij M, Valkema R, Krenning EP, de Jong M. Rolleman EJ, et al. Eur J Nucl Med Mol Imaging. 2007 May;34(5):763-771. doi: 10.1007/s00259-006-0291-3. Epub 2006 Dec 5. Eur J Nucl Med Mol Imaging. 2007. PMID: 17146655

4

Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy.

Bernard B, Capello A, van Hagen M, Breeman W, Srinivasan A, Schmidt M, Erion J, van Gameren A, Krenning E, de Jong M. Bernard B, et al. Cancer Biother Radiopharm. 2004 Apr;19(2):173-80. doi: 10.1089/108497804323071940. Cancer Biother Radiopharm. 2004. PMID: 15186597

5

Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948.

Verwijnen S, Capello A, Bernard B, van den Aardweg G, Konijnenberg M, Breeman W, Krenning E, de Jong M. Verwijnen S, et al. Cancer Biother Radiopharm. 2004 Jun;19(3):285-92. doi: 10.1089/1084978041425098. Cancer Biother Radiopharm. 2004. PMID: 15285875

6

Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide.

Capello A, Krenning EP, Breeman WA, Bernard BF, de Jong M. Capello A, et al. Among authors: bernard bf. J Nucl Med. 2003 Jan;44(1):98-104. J Nucl Med. 2003. PMID: 12515882 Free article.

7

The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.

Breeman WA, van der Wansem K, Bernard BF, van Gameren A, Erion JL, Visser TJ, Krenning EP, de Jong M. Breeman WA, et al. Among authors: bernard bf. Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):312-5. doi: 10.1007/s00259-002-1054-4. Epub 2002 Nov 29. Eur J Nucl Med Mol Imaging. 2003. PMID: 12552352

8

Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.

Capello A, Krenning EP, Breeman WA, Bernard BF, Konijnenberg MW, de Jong M. Capello A, et al. Among authors: bernard bf. Cancer Biother Radiopharm. 2003 Oct;18(5):761-8. doi: 10.1089/108497803770418300. Cancer Biother Radiopharm. 2003. PMID: 14629824

9

Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+.

Breeman WA, De Jong MT, De Blois E, Bernard BF, De Jong M, Krenning EP. Breeman WA, et al. Among authors: bernard bf. Nucl Med Biol. 2004 Aug;31(6):821-4. doi: 10.1016/j.nucmedbio.2004.03.008. Nucl Med Biol. 2004. PMID: 15246375

10

Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. de Jong M, et al. Among authors: bernard bf. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S. J Nucl Med. 2005. PMID: 15653647 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67 results

Search Page

Filters